The shingrix (zostavax) market research report is one of a series of new reports that provides shingrix (zostavax) market statistics, including shingrix (zostavax) industry global market size, regional shares, competitors with a shingrix (zostavax) market share, detailed shingrix (zostavax) market segments, market trends and opportunities, and any further data you may need to thrive in the shingrix (zostavax) industry. This shingrix (zostavax) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to rising geriatric population, increasing incidence of herpes zoster, rising incidence of chickenpox, increasing disease prevalence, and growing awareness about shingles and its complications. Major trends in the forecast period include innovative recombinant vaccines, advancements in vaccine development, a shift towards disease prevention over treatment, AI-powered vaccine research and development, and advanced biomarker identification for shingles susceptibility.
The growing adoption of vaccination is expected to drive the growth of the Shingrix (Zostavax) market. Vaccination, the process of administering a vaccine to stimulate the immune system to combat specific pathogens, is gaining widespread acceptance due to increased awareness of its effectiveness in preventing diseases and reducing their burden. Improvements in public health campaigns, healthcare infrastructure, and global vaccination initiatives have further bolstered the adoption of vaccination. Shingrix is an effective vaccine offering protection against shingles and its complications, particularly for adults over 50, significantly reducing the risk of shingles recurrence and post-herpetic neuralgia. For example, in May 2024, a study published by the Journal of the American Medical Association (JAMA) reported a 46% increase in shingles vaccinations covered by Medicare Part D in the year after the implementation of the IRA policy in January 2023. Additionally, the Australian government’s 2022 COVID-19 vaccination initiative ensured that over 34 million primary vaccinations and boosters were administered by mid-2022, with significant involvement from general practices, especially in rural areas. As vaccination adoption continues to grow, so does the market for Shingrix.
An important trend in the shingrix (Zostavax) market is the development of innovative, non-live, recombinant subunit vaccines that enhance vaccine efficacy and address immune system decline in aging populations. These vaccines include specific protein components from a pathogen along with an adjuvant to boost the immune response. In September 2024, GSK plc launched the Shingrix recombinant Zoster Vaccine (RZV), a non-live vaccine that offers up to 97% efficacy in preventing shingles and post-herpetic neuralgia. RZV is intended for adults aged 50 and older, as well as immunocompromised individuals aged 18 and above, with a two-dose intramuscular regimen. The ZOE-50 study showed that RZV provided up to 97% efficacy in adults aged 50 and above over three years, with recent data showing sustained efficacy of over 80% for 6-10 years after vaccination.
In October 2023, GSK plc entered a partnership with Chongqing Zhifei, a Chinese biotechnology company specializing in vaccine development and distribution, to expand the reach of Shingrix in China. This partnership aims to increase the market presence of Shingrix in the world’s second-largest pharmaceutical market, leveraging Chongqing Zhifei's local expertise in vaccine manufacturing and distribution.
The countries covered in the shingrix (zostavax) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Shingrix (Zostavax) is a vaccine designed to prevent shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus. It is primarily used to immunize adults, especially those aged 50 and older, to reduce the risk of developing shingles and its complications.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main formulations of Shingrix (Zostavax) include recombinant vaccines (Shingrix) and live-attenuated vaccines (Zostavax). The recombinant vaccine (Shingrix) is a non-live vaccine created using recombinant DNA technology to prevent shingles. It stimulates the immune system by introducing a protein from the varicella-zoster virus, providing strong protection against the disease. The indications for Shingrix include the prevention of shingles and post-herpetic neuralgia, with distribution through hospital pharmacies and retail pharmacies.
The shingrix (zostavax) market consists of sales of single-dose vials and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising geriatric population, increasing incidence of herpes zoster, rising incidence of chickenpox, increasing disease prevalence, and growing awareness about shingles and its complications. Major trends in the forecast period include innovative recombinant vaccines, advancements in vaccine development, a shift towards disease prevention over treatment, AI-powered vaccine research and development, and advanced biomarker identification for shingles susceptibility.
The growing adoption of vaccination is expected to drive the growth of the Shingrix (Zostavax) market. Vaccination, the process of administering a vaccine to stimulate the immune system to combat specific pathogens, is gaining widespread acceptance due to increased awareness of its effectiveness in preventing diseases and reducing their burden. Improvements in public health campaigns, healthcare infrastructure, and global vaccination initiatives have further bolstered the adoption of vaccination. Shingrix is an effective vaccine offering protection against shingles and its complications, particularly for adults over 50, significantly reducing the risk of shingles recurrence and post-herpetic neuralgia. For example, in May 2024, a study published by the Journal of the American Medical Association (JAMA) reported a 46% increase in shingles vaccinations covered by Medicare Part D in the year after the implementation of the IRA policy in January 2023. Additionally, the Australian government’s 2022 COVID-19 vaccination initiative ensured that over 34 million primary vaccinations and boosters were administered by mid-2022, with significant involvement from general practices, especially in rural areas. As vaccination adoption continues to grow, so does the market for Shingrix.
An important trend in the shingrix (Zostavax) market is the development of innovative, non-live, recombinant subunit vaccines that enhance vaccine efficacy and address immune system decline in aging populations. These vaccines include specific protein components from a pathogen along with an adjuvant to boost the immune response. In September 2024, GSK plc launched the Shingrix recombinant Zoster Vaccine (RZV), a non-live vaccine that offers up to 97% efficacy in preventing shingles and post-herpetic neuralgia. RZV is intended for adults aged 50 and older, as well as immunocompromised individuals aged 18 and above, with a two-dose intramuscular regimen. The ZOE-50 study showed that RZV provided up to 97% efficacy in adults aged 50 and above over three years, with recent data showing sustained efficacy of over 80% for 6-10 years after vaccination.
In October 2023, GSK plc entered a partnership with Chongqing Zhifei, a Chinese biotechnology company specializing in vaccine development and distribution, to expand the reach of Shingrix in China. This partnership aims to increase the market presence of Shingrix in the world’s second-largest pharmaceutical market, leveraging Chongqing Zhifei's local expertise in vaccine manufacturing and distribution.
The key company operating in the shingrix (zostavax) market is GSK plc
North America was the largest region in the shingrix (zostavax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in shingrix (zostavax) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the shingrix (zostavax) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Shingrix (Zostavax) is a vaccine designed to prevent shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus. It is primarily used to immunize adults, especially those aged 50 and older, to reduce the risk of developing shingles and its complications.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main formulations of Shingrix (Zostavax) include recombinant vaccines (Shingrix) and live-attenuated vaccines (Zostavax). The recombinant vaccine (Shingrix) is a non-live vaccine created using recombinant DNA technology to prevent shingles. It stimulates the immune system by introducing a protein from the varicella-zoster virus, providing strong protection against the disease. The indications for Shingrix include the prevention of shingles and post-herpetic neuralgia, with distribution through hospital pharmacies and retail pharmacies.
The shingrix (zostavax) market consists of sales of single-dose vials and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Shingrix (Zostavax) Market Characteristics4. Shingrix (Zostavax) Market Trends And Strategies5. Shingrix (Zostavax) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Shingrix (Zostavax) Pricing Analysis & Forecasts30. Global Shingrix (Zostavax) Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Shingrix (Zostavax) Market32. Recent Developments In The Shingrix (Zostavax) Market
3. Shingrix (Zostavax) Market Biologic Drug Characteristics
6. Global Shingrix (Zostavax) Growth Analysis And Strategic Analysis Framework
8. Shingrix (Zostavax) Market Segmentation
9. Global Shingrix (Zostavax) Epidemiology Of Clinical Indications
10. Shingrix (Zostavax) Market Regional And Country Analysis
11. Asia-Pacific Shingrix (Zostavax) Market
12. China Shingrix (Zostavax) Market
13. India Shingrix (Zostavax) Market
14. Japan Shingrix (Zostavax) Market
15. Australia Shingrix (Zostavax) Market
16. South Korea Shingrix (Zostavax) Market
17. Western Europe Shingrix (Zostavax) Market
18. UK Shingrix (Zostavax) Market
19. Germany Shingrix (Zostavax) Market
20. France Shingrix (Zostavax) Market
21. Eastern Europe Shingrix (Zostavax) Market
22. North America Shingrix (Zostavax) Market
23. USA Shingrix (Zostavax) Market
24. Canada Shingrix (Zostavax) Market
25. South America Shingrix (Zostavax) Market
26. Middle East Shingrix (Zostavax) Market
27. Africa Shingrix (Zostavax) Market
28. Shingrix (Zostavax) Market Competitive Landscape And Company Profiles
29. Global Shingrix (Zostavax) Market Pipeline Analysis
33. Shingrix (Zostavax) Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Shingrix (Zostavax) Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on shingrix (zostavax) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for shingrix (zostavax) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The shingrix (zostavax) market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Formulation: Recombinant Vaccine (Shingrix); Live Attenuated Vaccine (Zostavax)2) By Indication: Shingles Prevention; Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy
Key Companies Profiled: GSK plc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- GSK plc
